Clinical Trial Update: A Study of BMS-833923 With Cisplatin and Capecitabine in Inoperable, Metastatic Gastric, Gastroesophageal, or Esophageal Adenocarcinomas [Phase 1]

View source ↗

Summary

Phase 1 study of the BMS-833923 investigational agent in combination with cisplatin and capecitabine in patients with inoperable, metastatic gastric, gastroesop…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer
• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• BMS-833923
• CISPLATIN (cisplatin)
• Capecitabine (capecitabine)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Stomach Neoplasms, Esophageal Neoplasms | Phase 1 | Status: COMPLETED